Literature DB >> 11518004

The course of the terminal phase in patients with amyotrophic lateral sclerosis.

C Neudert1, D Oliver, M Wasner, G D Borasio.   

Abstract

The fear of "choking to death" is on the mind of most patients suffering from amyotrophic lateral sclerosis (ALS). So far, however, there have been no systematic surveys concerning the dying phase in a general ALS population. We therefore performed a structured telephone interview with the relatives of 121 patients who died from ALS and were followed by the Motor Neuron Outpatient Clinic of the Department of Neurology, University of Munich, Germany. These data are compared with those obtained by a retrospective analysis of medical records of 50 ALS patients who were followed by the Wisdom Hospice, Rochester, UK. The data show that most ALS patients (Germany 88%, UK 98%) died peacefully, and no patient "choked to death". The symptoms most frequently reported for the last 24 hours were dyspnoea, coughing, anxiety and restlessness. Around half (G 55%, UK 52%) of the patients died at home. The main palliative measures in place during the terminal phase were: home mechanical ventilation (G 21%, UK 0%), percutaneous endoscopic gastrostomy (G 27%, UK 14%), morphine (G 27%, UK 82%) and benzodiazepines (G 32%, UK 64%). The use of these palliative measures was judged to be beneficial by almost all relatives. These data support the hypothesis of a peaceful death process in ALS and should be communicated to patients and their relatives, at the latest after the onset of dyspnoea, to relieve unwarranted fears.

Entities:  

Mesh:

Year:  2001        PMID: 11518004     DOI: 10.1007/s004150170140

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  23 in total

1.  Legalising active euthanasia and physician assisted suicide. Assisted suicide is not always as easy as suggested.

Authors:  David Oliver; Jackie Fisher
Journal:  BMJ       Date:  2002-04-06

Review 2.  Management of motor neurone disease.

Authors:  R S Howard; R W Orrell
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

Review 3.  Diagnostic investigation and multidisciplinary management in motor neuron disease.

Authors:  J A Rocha; C Reis; F Simões; J Fonseca; J Mendes Ribeiro
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

4.  Quality of life of ALS and LIS patients with and without invasive mechanical ventilation.

Authors:  Marie-Christine Rousseau; Stéphane Pietra; José Blaya; Anne Catala
Journal:  J Neurol       Date:  2011-04-02       Impact factor: 4.849

5.  Requests for euthanasia: origin of suffering in ALS, heart failure, and cancer patients.

Authors:  Maud Maessen; Jan H Veldink; Leonard H van den Berg; Henrike J Schouten; Gerrit van der Wal; Bregje D Onwuteaka-Philipsen
Journal:  J Neurol       Date:  2010-02-11       Impact factor: 4.849

Review 6.  Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease.

Authors:  Johannes Brettschneider; Jerome Kurent; Albert Ludolph
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

Review 7.  Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management.

Authors:  Anja Kurt; Femke Nijboer; Tamara Matuz; Andrea Kübler
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 8.  Management of respiratory symptoms in ALS.

Authors:  Orla Hardiman
Journal:  J Neurol       Date:  2010-11-17       Impact factor: 4.849

9.  [Elective termination of respiratory therapy in amyotrophic lateral sclerosis].

Authors:  T Meyer; J S Dullinger; C Münch; J-P Keil; E Hempel; S Rosseau; N Borisow; P Linke
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

Review 10.  Management of amyotrophic lateral sclerosis.

Authors:  Philippe Corcia; Vincent Meininger
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.